These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12271179)

  • 1. People with Alzheimer's disease are denied drugs.
    Scott H
    Br J Nurs; 2000 Nov 9-22; 9(20):2120. PubMed ID: 12271179
    [No Abstract]   [Full Text] [Related]  

  • 2. Counting costs. Patients will suffer from limits on Alzheimer's drugs.
    Page S
    Nurs Stand; 2005 May 25-31; 19(37):24-5. PubMed ID: 15938410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The post-modern world of Alzheimer's disease trials: how much is an ADAS-cog point worth in central London?
    Schneider LS
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):9-13. PubMed ID: 16353164
    [No Abstract]   [Full Text] [Related]  

  • 4. Harmonisation of availability of drugs for Alzheimer's disease.
    Winblad B
    Lancet; 1999 Jul; 354(9174):257. PubMed ID: 10421337
    [No Abstract]   [Full Text] [Related]  

  • 5. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Bosanquet N; Yeates A
    Pharmacoeconomics; 2006; 24(6):623-5; author reply 625-6. PubMed ID: 16761908
    [No Abstract]   [Full Text] [Related]  

  • 6. NICE vindicated in UK's High Court.
    Horton R
    Lancet; 2007 Aug; 370(9587):547-8. PubMed ID: 17707735
    [No Abstract]   [Full Text] [Related]  

  • 7. Appeal Court rules that NICE procedure was unfair.
    Dyer C
    BMJ; 2008 May; 336(7652):1035. PubMed ID: 18467392
    [No Abstract]   [Full Text] [Related]  

  • 8. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
    Khang P; Weintraub N; Espinoza RT
    J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
    [No Abstract]   [Full Text] [Related]  

  • 9. Patients with mild Alzheimer's disease should have access to drugs, says draft NICE guidance.
    Kmietowicz Z
    BMJ; 2010 Oct; 341():c5562. PubMed ID: 20926475
    [No Abstract]   [Full Text] [Related]  

  • 10. Experts disagree over NICE's approach for assessing drugs.
    Hoey R
    Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791
    [No Abstract]   [Full Text] [Related]  

  • 11. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
    Whalen J
    Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
    [No Abstract]   [Full Text] [Related]  

  • 12. Alzheimer's disease. Three-score years and then?
    Bryan J
    Health Serv J; 1998 Aug; 108(5619):suppl 4-5, 7-8. PubMed ID: 10185456
    [No Abstract]   [Full Text] [Related]  

  • 13. Donepezil and Alzheimer's dementia.
    Earl-Slater A; Walley T
    Clin Perform Qual Health Care; 2000; 8(1):47-51. PubMed ID: 11183967
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of Alzheimer's disease utilising the best available evidence-based medicine -- utopia?].
    Stoppe G; Pirk O; Haupt M
    Gesundheitswesen; 2005 Jan; 67(1):20-6. PubMed ID: 15672302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economics: basic principles and application in mental health.
    Suh GH
    Int Psychogeriatr; 2007 Dec; 19(6):993-1002. PubMed ID: 18161066
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
    Ward A; Caro JJ; Getsios D; Ishak K; O'Brien J; Bullock R;
    Int J Geriatr Psychiatry; 2003 Aug; 18(8):740-7. PubMed ID: 12891643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.
    Versijpt J
    Acta Neurol Belg; 2012 Jun; 112(2):141-5. PubMed ID: 22476975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The costs of Alzheimer's disease treatment: the rationale of acetylcholinesterase inhibitors use?].
    Sobów TM; Kłoszewska I
    Psychiatr Pol; 1999; 33(5):761-7. PubMed ID: 10761441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A contribution to the current discussion on anti-dementia drugs in Germany].
    Jessen F; Maier W
    Nervenarzt; 2007 May; 78(5):491-2, 494, 496-7. PubMed ID: 17106726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.